Cullinan Therapeutics (CGEM) Free Cash Flow: 2020-2024
Historic Free Cash Flow for Cullinan Therapeutics (CGEM) over the last 5 years, with Dec 2024 value amounting to -$145.3 million.
- Cullinan Therapeutics' Free Cash Flow rose 29.90% to -$18.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$134.5 million, marking a year-over-year decrease of 5.23%. This contributed to the annual value of -$145.3 million for FY2024, which is 8.05% down from last year.
- Cullinan Therapeutics' Free Cash Flow amounted to -$145.3 million in FY2024, which was down 8.05% from -$134.5 million recorded in FY2023.
- In the past 5 years, Cullinan Therapeutics' Free Cash Flow registered a high of -$29.8 million during FY2020, and its lowest value of -$145.3 million during FY2024.
- For the 3-year period, Cullinan Therapeutics' Free Cash Flow averaged around -$135.9 million, with its median value being -$134.5 million (2023).
- Data for Cullinan Therapeutics' Free Cash Flow shows a maximum YoY tumbled of 194.24% (in 2022) over the last 5 years.
- Over the past 5 years, Cullinan Therapeutics' Free Cash Flow (Yearly) stood at -$29.8 million in 2020, then tumbled by 45.84% to -$43.4 million in 2021, then slumped by 194.24% to -$127.8 million in 2022, then fell by 5.23% to -$134.5 million in 2023, then declined by 8.05% to -$145.3 million in 2024.